Table 1.
| |||||||||
---|---|---|---|---|---|---|---|---|---|
|
|
IC50a,b (μM)
|
|||||||
Cmpd | R5 | R6 | R7 | R3′ | X | HL-60c | Hep3Bc | NCI-H460c | Detroit551c |
|
|
|
|||||||
6a | CH3 | H | H | OCH3 | - | 0.03 | 0.13 | 0.18 | >5.0 |
7a | CH3 | H | H | OH | - | 0.03 | 0.17 | 0.20 | >50 |
6b | H | CH3 | H | OCH3 | - | 0.06 | 0.12 | 0.14 | >2.5 |
7b | H | CH3 | H | OH | - | 0.08 | 0.44 | 0.45 | >2.5 |
6c | CH3 | H | CH3 | OCH3 | - | 0.33 | 0.73 | 0.75 | >50 |
7c | CH3 | H | CH3 | OH | - | 0.29 | 0.68 | 1.30 | >100 |
6d | H | Cl | H | OCH3 | - | 0.03 | 0.10 | 0.10 | >50 |
7d | H | Cl | H | OH | - | 0.11 | 0.34 | 0.20 | >100 |
6e | H | F | H | OCH3 | - | 0.07 | 0.20 | 0.24 | >5.0 |
7e | H | F | H | OH | - | 0.14 | 0.38 | 0.70 | >100 |
7f | OH | H | H | F | - | 0.82 | 1.82 | 2.48 | >100 |
6g | H | OCH3 | H | F | - | 0.02 | 0.02 | 0.05 | >10 |
7g | H | OH | H | F | - | 0.08 | 0.16 | 0.86 | >100 |
6h | H | OCH3 | H | - | –CH=CH- | 0.04 | 0.05 | 0.85 | >25 |
7h | H | OH | H | - | –CH=CH- | 0.48 | 0.46 | 1.34 | >100 |
6i | H | OCH3 | H | - | S | 0.04 | 0.09 | 0.16 | >10 |
7i | H | OH | H | - | S | 0.57 | 1.07 | 0.39 | 10 |
Taxol | - | - | - | - | - | 0.002 | 0.50 | 0.005 | NTd |
Data was presented as IC50 (μM, the concentration of 50% proliferation-inhibitory effect).
Human tumor cells were treated with different concentrations of samples for 48 h.
HL-60, human leukemia cell line; Hep3B, human hepatoma cell line; NCI-H460, non-small cell lung cancer cell line; Detroit 551, human skin fibroblast cell line.
NT = not tested.